Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Changes in HPV prevalence in Danish women with vulvar cancer during 28 years - A nationwide study of >1300 cancer cases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prognostic value of the 2018 FIGO staging system for cervical cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Potential Targeted Therapies in Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. An overview of Clinical Quality Registries (CQRs) on gynecological oncology worldwide

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. miRNA Expression in Ovarian Cancer in Fresh Frozen, Formalin-fixed Paraffin-embedded and Plasma Samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Alicia Leon-Castillo
  • Nanda Horeweg
  • Elke E M Peters
  • Tessa Rutten
  • Natalja Ter Haar
  • Vincent T H B M Smit
  • Cor D Kroon
  • Marie Boennelycke
  • Estrid Hogdall
  • Claus Hogdall
  • Remi R A Nout
  • Carien L Creutzberg
  • Gitte Ortoft
  • Tjalling Bosse
Vis graf over relationer

INTRODUCTION: The clinical role of the molecular endometrial cancer (EC) classification has not been fully explored in patients staged with lymphadenectomy or without adjuvant treatment, conditions that could potentially moderate the prognostic value of the classification. We aimed to evaluate the clinical outcome of the molecular subgroups in patients with high-grade EC staged by lymphadenectomy and those without adjuvant treatment.

METHODS: DNA-sequencing for the detection of pathogenic POLE-exonuclease domain mutations and immunohistochemistry for mismatch repair (MMR) proteins and p53 expression were performed on 412 high-grade EC from the Danish Gynaecological Cancer Database (2005-2012) to classify them as POLE-ultramutated (POLEmut), MMR-deficient (MMRd), p53-mutant (p53abn), or no specific molecular profile (NSMP). Patients with stage IV or residual disease after surgery were excluded. Kaplan-Meier method, log-rank test and Cox proportional hazard models were used for analysis.

RESULTS: Molecular analysis was successful in 367 EC; 251 patients had undergone lymphadenectomy. Five-year recurrence rates in this subgroup of patients was 36.7% for women with p53abn EC, 0.0% for POLEmut EC, 13.4% for MMRd EC and 42.9% for NSMP EC (p < 0.001). Similar results were observed among stage IA-IB patients. Among patients without adjuvant treatment (n = 264), none with POLEmut EC (n = 26) had a recurrence.

CONCLUSION: The molecular EC classification has strong prognostic value, independent of clinicopathological factors, also among high-grade EC patients staged by lymphadenectomy and those without adjuvant treatment. The unfavourable prognosis of early-stage p53abn EC is not due to undetected lymph node metastasis, and the indolent behaviour of POLEmut EC is independent of adjuvant treatment.

OriginalsprogEngelsk
TidsskriftGynecologic Oncology
Vol/bind164
Udgave nummer3
Sider (fra-til)577-586
Antal sider10
ISSN0090-8258
DOI
StatusUdgivet - mar. 2022

Bibliografisk note

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

ID: 79860304